Flying The Web For News.
  • Epiphany
    Epiphany
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: European Commission approves RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

Details
Category: Globe NewsWire News Distribution Service

This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line treatment of patients with EGFR-mutated NSCLC1 In the Phase 3 MARIPOSA study, amivantamab plus lazertinib significantly reduced the risk of disease progression or death by 30 percent versus osimertinib monotherapy1


Posted: 2024-12-30 08:00:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | european | commission | approves


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: European Commission approves RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer - Newscast

EU Approves Synopsys and Ansys Merger with Divestment Conditions

Mon, 13 Jan 2025 13:30:00 GMT The European Commission conditionally approved the $35 billion acquisition of simulation software company Ansys by Synopsys on Friday.

EU approves $35B Synopsys and Ansys merger, subject to divestment conditions

Fri, 10 Jan 2025 11:16:00 GMT The European Commission has given the green light for Synopsys to acquire Ansys in what will be a $35 billion transaction.

European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy

Thu, 09 Jan 2025 00:00:00 GMT a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia® (defatted powder of ...

European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy

Wed, 08 Jan 2025 16:01:00 GMT BAAR, Switzerland — Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication ...

European Commission Approves $4.24B German Aid for Floating LNG Terminals

Mon, 23 Dec 2024 01:56:00 GMT A EUR 4.06 billion ($4.24 billion) direct grant by the German government for four gas storage and regasification units (FSRUs) has received state aid rules clearance from the European Commission.


Blow Us A Whistle